Complex Generics Pipeline
Various
Key Facts
About Aurobindo Pharma
Founded in 1986, Aurobindo Pharma has grown from an API manufacturer into a global generics powerhouse with a mission to make medicines affordable and accessible worldwide. Its core strategy leverages deep vertical integration, significant manufacturing scale (29 facilities producing 50+ billion formulation units annually), and a strategic pivot towards high-value complex generics, injectables, and biosimilars. Key achievements include a portfolio of over 830 ANDA filings in the US with 600+ approvals, leadership in antiretroviral therapies, and the recent inauguration of a flagship Penicillin-G facility, underscoring its commitment to backward integration and supply chain resilience.
View full company profileTherapeutic Areas
Other Various Drugs
| Drug | Company | Phase |
|---|---|---|
| New Generic Approvals | China SXT Pharmaceuticals | Application Submitted / BE Stage |
| New Dosage Form Development | Universe Pharmaceuticals | Development |
| New TCM Formula Registration | Universe Pharmaceuticals | Development |
| CBD/THC Oil Formulation | Avecho Biotechnology | Preclinical |
| Bag APIs | ChemWerth | Approved |
| Oral APIs | ChemWerth | Approved |
| Companion Diagnostics Development | Kiffik Biomedical | Pre-clinical |
| Portfolio of Complex Generics & 505(b)(2) Products | Alvogen | Approved/Commercial |
| Portfolio of 40+ products | Praxgen Pharmaceuticals | Development |
| Drug Repositioning Service | Biovista | Service |
| Custom Control Development | Anchor Molecular | Development/Commercial |
| Portfolio from Steriscience Partnership | Armas Pharmaceuticals | ANDA Development/Filing |